FR3093419B1 - Composition et procédé associé de mesure de l’observance thérapeutique - Google Patents

Composition et procédé associé de mesure de l’observance thérapeutique Download PDF

Info

Publication number
FR3093419B1
FR3093419B1 FR1902393A FR1902393A FR3093419B1 FR 3093419 B1 FR3093419 B1 FR 3093419B1 FR 1902393 A FR1902393 A FR 1902393A FR 1902393 A FR1902393 A FR 1902393A FR 3093419 B1 FR3093419 B1 FR 3093419B1
Authority
FR
France
Prior art keywords
composition
detection agent
therapeutic compliance
associated method
medicinal substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1902393A
Other languages
English (en)
Other versions
FR3093419A1 (fr
Inventor
Jean-Pierre Alcaraz
Donald Martin
Philippe Cinquin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Polytechnique de Grenoble
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Polytechnique de Grenoble
Universite Grenoble Alpes
Centre Hospitalier Universitaire Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1902393A priority Critical patent/FR3093419B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Polytechnique de Grenoble, Universite Grenoble Alpes, Centre Hospitalier Universitaire Grenoble Alpes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/EP2020/055736 priority patent/WO2020182581A1/fr
Priority to JP2021553097A priority patent/JP2022524102A/ja
Priority to US17/437,380 priority patent/US20220142565A1/en
Priority to KR1020217032545A priority patent/KR20210141974A/ko
Priority to CN202080019725.9A priority patent/CN113631083A/zh
Priority to EP20707128.3A priority patent/EP3934512A1/fr
Publication of FR3093419A1 publication Critical patent/FR3093419A1/fr
Application granted granted Critical
Publication of FR3093419B1 publication Critical patent/FR3093419B1/fr
Priority to IL286111A priority patent/IL286111A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/073—Intestinal transmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/076—Permanent implantations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6861—Capsules, e.g. for swallowing or implanting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device

Abstract

Composition et procédé associé de mesure de l’observance thérapeutique. L’invention concerne le domaine de l’observance thérapeutique et plus particulièrement une composition 10 comprenant : au moins une substance médicamenteuse 13, au moins un agent de détection 11, la substance médicamenteuse 13 étant différente de l’agent de détection 11, la composition étant configurée de sorte que l’agent de détection 11 permette d’indiquer l’ingestion de la substance médicamenteuse 13. La composition est essentiellement tel que l’agent de détection 11 comprend au moins un hydrure 110 propre et destiné à se dissoudre au contact d’un milieu aqueux dans le corps humain ou animal 2 en libérant du dihydrogène. La libération du dihydrogène permet la détection en temps réel de l’ingestion de la composition 10. En outre, la production de la composition 10 présente un coût de production acceptable pour l’industrie pharmaceutique. Ainsi, la composition 10 est adaptée à un très large déploiement. Figure pour l’abrégé : Fig. 6
FR1902393A 2019-03-08 2019-03-08 Composition et procédé associé de mesure de l’observance thérapeutique Active FR3093419B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1902393A FR3093419B1 (fr) 2019-03-08 2019-03-08 Composition et procédé associé de mesure de l’observance thérapeutique
JP2021553097A JP2022524102A (ja) 2019-03-08 2020-03-04 治療遵守を測定するための組成物及びその方法
US17/437,380 US20220142565A1 (en) 2019-03-08 2020-03-04 Composition for measuring medication compliance and method thereof
KR1020217032545A KR20210141974A (ko) 2019-03-08 2020-03-04 치료 순응도를 측정하기 위한 조성물 및 그 방법
PCT/EP2020/055736 WO2020182581A1 (fr) 2019-03-08 2020-03-04 Composition et procédé associé de mesure de l'observance thérapeutique
CN202080019725.9A CN113631083A (zh) 2019-03-08 2020-03-04 用于测量治疗依从性的组合物及其方法
EP20707128.3A EP3934512A1 (fr) 2019-03-08 2020-03-04 Composition et procédé associé de mesure de l'observance thérapeutique
IL286111A IL286111A (en) 2019-03-08 2021-09-02 Composition for measuring therapeutic compliance and method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1902393A FR3093419B1 (fr) 2019-03-08 2019-03-08 Composition et procédé associé de mesure de l’observance thérapeutique
FR1902393 2019-03-08

Publications (2)

Publication Number Publication Date
FR3093419A1 FR3093419A1 (fr) 2020-09-11
FR3093419B1 true FR3093419B1 (fr) 2021-06-18

Family

ID=67185393

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1902393A Active FR3093419B1 (fr) 2019-03-08 2019-03-08 Composition et procédé associé de mesure de l’observance thérapeutique

Country Status (8)

Country Link
US (1) US20220142565A1 (fr)
EP (1) EP3934512A1 (fr)
JP (1) JP2022524102A (fr)
KR (1) KR20210141974A (fr)
CN (1) CN113631083A (fr)
FR (1) FR3093419B1 (fr)
IL (1) IL286111A (fr)
WO (1) WO2020182581A1 (fr)

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233459A1 (en) * 2003-11-26 2005-10-20 Melker Richard J Marker detection method and apparatus to monitor drug compliance
WO2001034024A1 (fr) * 1999-11-08 2001-05-17 University Of Florida Research Foundation, Inc. Procede de detection de marqueur et appareil de surveillance de l'observance therapeutique de medicaments
US20030194374A1 (en) * 2001-01-17 2003-10-16 Xanodyne Pharmacal, Inc. Compositions including a visual marker and method of use thereof
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
EP2671507A3 (fr) * 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Système pharma-informatique
WO2007013952A2 (fr) * 2005-07-20 2007-02-01 Euliano Neil R Systeme d'observance therapeutique et procedes associes
US9047746B1 (en) * 2005-07-20 2015-06-02 Neil Euliano Electronic medication compliance monitoring system and associated methods
CN101252918A (zh) * 2005-07-22 2008-08-27 陶氏环球技术公司 利用声音检测进行口服药物依从性监测
GB0515353D0 (en) * 2005-07-27 2005-08-31 Psimedica Ltd Food
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
US7927284B2 (en) * 2005-09-16 2011-04-19 Cardiac Pacemakers, Inc. Quantifying hemodynamic response to drug therapy using implantable sensor
US20070135691A1 (en) * 2005-12-12 2007-06-14 General Electric Company Medicament compliance monitoring system, method, and medicament container
CN102323984A (zh) * 2006-03-30 2012-01-18 陶氏环球技术有限责任公司 用于监控并分析体内用药方案的依从的方法与系统
CN101695443A (zh) * 2006-04-25 2010-04-21 陶氏环球技术公司 使用磁场传感器的口服药依从性监视
JP5134793B2 (ja) * 2006-08-04 2013-01-30 有限会社スプリング 水中の溶存水素を活性化および安定化する方法
US20080213904A1 (en) 2006-08-24 2008-09-04 Sliwa John W Monitoring drug compliance, food-intake or toxin-intake using non-invasively-read labels
KR20080030835A (ko) * 2006-10-02 2008-04-07 쎄라피콘 에스.알.엘. 약학 조성물
JP2010519553A (ja) * 2007-02-22 2010-06-03 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 服薬遵守モニタリングシステム
EP2168196B1 (fr) * 2007-06-29 2018-12-26 Universite Joseph Fourier - Grenoble 1 Dispositif de membrane artificielle biomimétique
JP2010535801A (ja) * 2007-08-06 2010-11-25 シノシア・セラピューティクス・インコーポレイテッド 依存症治療方法
KR20110104079A (ko) 2009-01-06 2011-09-21 프로테우스 바이오메디컬, 인코포레이티드 약제학적 투여량 전달 시스템
SG10201810784SA (en) * 2009-04-28 2018-12-28 Proteus Digital Health Inc Highly Reliable Ingestible Event Markers And Methods For Using The Same
JP5845172B2 (ja) * 2009-05-01 2016-01-20 アデア ファーマスーティカルズ，インコーポレイテッド 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物
FR2991325B1 (fr) * 2012-05-31 2015-01-16 Centre Nat Rech Scient Solide hybride organique inorganique ameliore a surface externe modifiee
CN104470571B (zh) * 2012-07-18 2017-06-20 皇家飞利浦有限公司 用于呼吸治疗中经改进的顺应性的系统和方法
DE102012217387A1 (de) * 2012-09-26 2014-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutische Nutzung von Wasserstoffmolekülen
EP4159248A1 (fr) * 2013-12-10 2023-04-05 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés pour faire adhérer des surfaces tissulaires et des matériaux et utilisations biomédicales de ceux-ci
WO2015134390A1 (fr) * 2014-03-04 2015-09-11 University Of Florida Research Foundation Dispositif de suivi de l'adhésion à un traitement
FR3021872B1 (fr) * 2014-06-05 2018-07-13 Koninklijke Philips N.V. Procede et dispositif de detection au sein d'un dispositif d'assistance respiratoire de l'aggravation de l'etat cardio-respiratoire d'un patient
CN106796195A (zh) * 2014-09-02 2017-05-31 墨尔本皇家理工大学 气体传感器纳米复合物膜
WO2016131642A1 (fr) * 2015-02-17 2016-08-25 Koninklijke Philips N.V. Système de blanchiment des dents monocouche
WO2017008018A1 (fr) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Capteurs mis au point par génie génétique pour la détection in vivo de saignement
WO2017223043A1 (fr) * 2016-06-22 2017-12-28 University Of Florida Research Foundation, Inc. Capsules pharmaceutiques pour la surveillance de l'observance médicamenteuse et leurs procédés de formation
US11419519B2 (en) 2016-08-15 2022-08-23 Royal Melbourne Institute Of Technology Gas sensor capsule
AU2017311851B2 (en) 2016-08-17 2022-08-25 Pendave Pty Ltd An attachment for a tool
FR3059553B1 (fr) * 2016-12-07 2021-04-23 Univ Grenoble Alpes Dispositif implantable
FR3059558B1 (fr) 2016-12-07 2021-05-14 Univ Grenoble Alpes Systeme implantable
US20190015038A1 (en) * 2017-07-17 2019-01-17 Trutag Technologies, Inc. In vivo patient compliance monitoring
CN109224237A (zh) * 2018-09-20 2019-01-18 深圳市量子氢生物技术有限公司 一种医用氢气治疗仪

Also Published As

Publication number Publication date
US20220142565A1 (en) 2022-05-12
IL286111A (en) 2021-10-31
EP3934512A1 (fr) 2022-01-12
JP2022524102A (ja) 2022-04-27
CN113631083A (zh) 2021-11-09
WO2020182581A1 (fr) 2020-09-17
FR3093419A1 (fr) 2020-09-11
KR20210141974A (ko) 2021-11-23

Similar Documents

Publication Publication Date Title
MA52680A1 (fr) Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines
US5074677A (en) Center-free large roller bearing
Wong et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis
Cloutier et al. The prostanoid 15-deoxy-Δ12, 14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection
Aschner et al. Glial cells in neurotoxicity development
Markowitz et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults
Dalbeth et al. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis
Mendell et al. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin
HUP0101994A2 (hu) Eszköz valamely gyógyszervegyület vérparaméterekre gyakorolt hatásainak in vivo meghatározására, valamint alkalmazása
Suneetha Role of dimethyl fumarate in oxidative stress of multiple sclerosis: a review
Alsirawan et al. Development and validation of a simple HPLC method for the determination of ibuprofen sticking onto punch faces
Batu et al. Evaluation of prolidase activity and oxidative stress in patients with oral lichen planus and oral lichenoid contact reactions
KR880004314A (ko) 생리 활성물질 측정법
FR3093419B1 (fr) Composition et procédé associé de mesure de l’observance thérapeutique
Cressey et al. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study
Perram et al. Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
MA40937A (fr) Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation
Bakhsh et al. Nondestructive evaluation of microleakage in restored primary teeth using CP-OCT
AR037141A1 (es) Un metodo para identificar interacciones entre dos farmacos y una disposicion de screening de bibliotecas para determinar la interaccion de un farmaco de ensayo con un miembro de una biblioteca de farmacos en un ensayo
Ferraz et al. Validation of in vitro analytical method to measure papain activity in pharmaceutical formulations
FR3093428B1 (fr) Composition et dispositif associé de délivrance pour l’hydrogénothérapie
Reddy et al. A new stability-indicating RP-HPLC-PDA method for simultaneous estimation of glecaprevir and Pibrentasvir in tablet dosage form
DE60114472D1 (de) Verfahren zum auffinden von ozonverbrauchenden verbindungen
RU2788609C1 (ru) Способ профилактики хронической сулемовой коагулопатии у крыс в эксперименте

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200911

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: UNIVERSITE GRENOBLE ALPES, FR

Effective date: 20211130

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPE, FR

Effective date: 20211130

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR

Effective date: 20211130

Owner name: INSTITUT POLYTECHNIQUE DE GRENOBLE, FR

Effective date: 20211130

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6